TransMedics Group, Inc. Common Stock (TMDX) — Analysis Summary
TransMedics Group, Inc. Common Stock (TMDX) has a market cap of $3.18B with year-over-year revenue growth of +37.1%. Net margin stands at 31.4%. The stock trades at a P/E ratio of 21.0.
Key Takeaways
- Revenue changed +37.1% year-over-year
- Net margin of 31.4%
- P/E ratio of 21.0
Compared to other companies in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector, TMDX posted revenue growth of +37.1% and trades at a P/E of 21.0.
TransMedics Group, Inc. Common Stock (TMDX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Employees
898
Headquarters
ANDOVER, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.